The Korean Journal of Medicine

  • 제80권5호
  • /
  • Pages.510-523
  • /
  • 2011
  • /
  • 1738-9364(pISSN)
  • /
  • 2289-0769(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지

변비의 치료

Treatment of Constipation

  • 박무인 (고신대학교 의과대학 내과학교실)
  • Park, Moo-In (Department of Internal Medicine, Kosin University College of Medicine)
  • 발행 : 2011.05.01
⟨ 이전 논문 다음 논문 ⟩

초록

Constipation is a common gastrointestinal disease affecting approximately 16.5% of the population in Korea. Systemic diseasessuch as hypothyroidism or colon cancer and drugs can cause constipation in some patients with constipation, there is no obstructivemucosal or structural cause in the vast majority of patients with constipation. Evaluation for secondary causes of constipation isneeded to provide appropriate management. Once secondary causes have been excluded, constipation may be classified into normalor slow transit constipation, evacuation disorder of the spastic or flaccid varieties, or both. Treatment of chronic constipation basedon the underlying pathophysiology is generally successful. The aims of this review are to discuss the management of functionalconstipation based on guidelines for the treatment of constipation published in Korean Journal of Gastroenterology in 2011:lifestyle changes; bulking agents and stool softeners; osmotic agents; stimulant laxatives; prokinetics; biofeedback and surgicaltreatments. Exercise and dietary fiber are helpful in some patients with constipation. Laxatives including bulking agents, stoolsofteners, osmotic agents, stimulant laxatives have been found to be more effective than placebo at relieving symptoms ofconstipation. New enterokinetic agents such as 5-hydroxytryptamine-4 receptor agonists, intestinal secretagogues, and peripheralopioid antagonists could be effective in patients with constipation who cannot get adequate relief from current laxatives.Biofeedback could relieve symptoms in selected patients with constipation due to pelvic floor dyssynergia. Surgical treatments canbe helpful in some patients with refractory constipation.

키워드

참고문헌

  1. Garrigues V, Gálvez C, Ortiz V, Ponce M, Nos P, Ponce J. Prevalence of constipation: agreement among several criteria and evaluation of the diagnostic accuracy of qualifying symptoms and self-reported definition in a population-based survey in Spain. Am J Epidemiol 2004;159:520-526. https://doi.org/10.1093/aje/kwh072
  2. Lembo A, Camilleri M. Chronic constipation. N Engl J Med 2003;349:1360-1368. https://doi.org/10.1056/NEJMra020995
  3. Pare P, Ferrazzi S, Thompson WG, Irvine EJ, Rance L. An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol 2001;96:3130-3137. https://doi.org/10.1111/j.1572-0241.2001.05259.x
  4. Jun DW, Park HY, Lee OY, et al. A population-based study on bowel habits in a Korean community: prevalence of functional constipation and self-reported constipation. Dig Dis Sci 2006;51:1471-1477. https://doi.org/10.1007/s10620-006-9087-3
  5. Heaton KW, Radvan J, Cripps H, Mountford RA, Braddon FE, Hughes AO. Defecation frequency and timing, and stool form in the general population: a prospective study. Gut 1992;33:818-824. https://doi.org/10.1136/gut.33.6.818
  6. Camilleri M, Cowen T, Koch TR. Enteric neurodegeneration in ageing. Neurogastroenterol Motil 2008;20:185-196. https://doi.org/10.1111/j.1365-2982.2007.01072.x
  7. Wald A, Scarpignato C, Kamm MA, et al. The burden of constipation on quality of life: results of a multinational survey. Aliment Pharmacol Ther 2007;26:227-236. https://doi.org/10.1111/j.1365-2036.2007.03376.x
  8. Camilleri M, Bharucha AE. Behavioural and new pharmacological treatments for constipation: getting the balance right. Gut 2010; 59:1288-1296. https://doi.org/10.1136/gut.2009.199653
  9. Park MI, Shin JE, Myung SJ, et al. Guidelines for the Treatment of Constipation. Korean J Gastroenterol 2011;57:100-114. https://doi.org/10.4166/kjg.2011.57.2.100
  10. Hull C, Greco RS, Brooks DL. Alleviation of constipation in the elderly by dietary fiber supplementation. J Am Geriatr Soc 1980; 28;410-414.
  11. Sandman PO, Adolfsson R, Hallmans G, Nygren C, Nystrom L, Winblad B. Treatment of constipation with high-bran bread in long-term care of severely demented elderly patients. J Am Geriatr Soc 1983;31;289-293.
  12. Brown WJ, Mishra G, Lee C, Bauman A. Leisure time physical activity in Australian women: relationship with well being and symptoms. Res Q Exerc Sport 2000;71:206-216. https://doi.org/10.1080/02701367.2000.10608901
  13. Sullivan SN, Wong C, Heidenheim P. Does running cause gastrointestinal symptoms? A survey of 93 randomly selected runners compared with controls. N Z Med J 1994;107:328-331.
  14. Coenen C, Wegener M, Wedmann B, Schmidt G, Hoffmann S. Does physical excercise influence bowel transit time in healthy young men? Am J Gastroenterol 1992;87:292-295.
  15. Meshkinpour H, Kemp C, Fairshter R. Effect of aerobic exercise on mouth-to-cecum transit time. Gastroenterology 1989;96:938-941.
  16. Soffer EE, Summers RW, Gisolfi C. Effect of exercise on intestinal motility and transit in trained athletes. Am J Physiol 1991;260:G698-G702.
  17. Oteile GJ. Effect of moderate exercise on bowel habits. Gut 1991;32:941-944. https://doi.org/10.1136/gut.32.8.941
  18. Bringham SA, Cummings JH. Effect of exercise and physical fitness on large intestinal function. Gastroenterology 1989;97: 1389-1399.
  19. Keeling WF, Harris A, Martin BJ. Orocecal transit during mild exercise in women. J Appl Physiol 1990;68:1350-1353.
  20. Keeling WF, Martin BJ. Gastrointestinal transit during mild exercise. J Appl Physiol 1987;63:978-981.
  21. Rao SS, Beaty J, Chamberlain M, Lambert PG, Gisolfi C. Effects of acute graded exercise on human colonic motility. Am J Physiol 1999;276:G1221-G1226.
  22. Fenn GC, Wilkinson PD, Lee CE, Akbar FA. A general practice study of the efficacy of Regulan in functional constipation. Br J Clin Pract 1986;40:192-197.
  23. Ashraf W, Park F, Lof J, Quigley EM. Effects of psyllium therapy on stool characteristics, colon transit and anorectal function in chronic idiopathic constipation. Aliment Pharmacol Ther 1995;9: 639-647.
  24. Cheskin LJ, Kamal N, Crowell MD, Schuster MM, Whitehead WE. Mechanisms of constipation in older persons and effects of fiber compared with placebo. J Am Geriatr Soc 1995;43:666-669.
  25. McRorie JW, Daggy BP, Morel JG, Diersing PS, Miner PB, Robinson M. Psyllium is superior to docusate sodium for treatment of chronic constipation. Aliment Pharmacol Ther 1998; 12:491-497. https://doi.org/10.1046/j.1365-2036.1998.00336.x
  26. Eum J, Rhee KH, Cho YK, et al. Therapeutic effects of Agio (R) 18 g per day in patients with constipation dominant irritable bowel syndrome and chronic constipation. Korean J Neurogastroenterol Motil 2008;14:115-121.
  27. Kinnunen O, Salokannel J. Constipation in elderly long-stay patients: Its treatment by magnesium hydroxide and bulk laxative. Ann Clin Res 1987;19:321-323.
  28. Shin EK, Park SJ, Kim KJ, et al. Effect of combination pretreatment of polyethylene glycol solution and magnesium hydroxide for colonoscopy. Korean J Gastroenterol 2010;55: 232-236. https://doi.org/10.4166/kjg.2010.55.4.232
  29. Andorsky RI, Goldner F. Colonic lavage solution (polyethylene glycol electrolyte lavage solution) as a treatment for chronic constipation: a double-blind, placebo-controlled study. Am J Gastroenterol 1990;85:261-265.
  30. Klauser AG, Mühldorfer BE, Volderholzer WA, Wenzel G, Muller-Lissner SA. Polyethylene glycol 4000 for slow transit constipation. Z Gastroenterol 1995;33:5-8.
  31. Corazziari E, Badiali D, Habib FI, et al. Small volume isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in treatment of chronic nonorganic constipation. Dig Dis Sci 1996;41:1636-1642. https://doi.org/10.1007/BF02087913
  32. Freedman MD, Schwartz JH, Roby R, Fleisher S. Tolerance and efficacy of polyethylene glycol 3350/electrolyte solution versus lactulose in relieving opiate induced constipation: a doubleblinded placebo-controlled trial. J Clin Pharmacol 1997;37:904-907. https://doi.org/10.1002/j.1552-4604.1997.tb04264.x
  33. Attar A, Lémann M, Ferguson A, et al. Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation. Gut 1999;44:226-230. https://doi.org/10.1136/gut.44.2.226
  34. Bassotti G, Fiorella S, Roselli P, Modesto R. Use of polyethylene glycol solution in slow transit constipation. Ital J Gastroenterol Hepatol 1999;31(Supp 3):S255-S256.
  35. Cleveland MV, Flavin DP, Ruben RA, Epstein RM, Clark GE. New polyethylene glycol laxative for treatment of constipation in adults: a randomized, double-blind, placebo-controlled study. South Med J 2001;94:478-481.
  36. DiPalma JA, DeRidder PH, Orlando RC, Kolts BE, Cleveland MB. A randomized, placebo-controlled, multicenter study of the safety and efficacy of a new polyethylene glycol laxative. Am J Gastroenterol 2000;95:446-450. https://doi.org/10.1111/j.1572-0241.2000.01765.x
  37. DiPalma JA, Smith JR, Cleveland MB. Overnight efficacy of polyethylene glycol laxative. Am J Gastroenterol 2002;97: 1776-1779. https://doi.org/10.1111/j.1572-0241.2002.05840.x
  38. DiPalma JA, Cleveland MV, McGowan J, Herrera JL. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol 2007;102:1436-1441. https://doi.org/10.1111/j.1572-0241.2007.01199.x
  39. DiPalma JA, Cleveland MB, McGowan J, Herrera JL. A comparison of polyethylene glycol laxative and placebo for relief of constipation from constipating medications. South Med J 2007;100:1085-1090. https://doi.org/10.1097/SMJ.0b013e318157ec8f
  40. Bae SH. Long-term safety of PEG 4000 in children with chronic functional constipation: a biochemical perspective. Korean J Pediatr 2010;53:741-744. https://doi.org/10.3345/kjp.2010.53.7.741
  41. Sanders JF. Lactulose syrup assessed in a double-blind study of elderly constipated patients. J Am Geriatr Soc 1978;26:236-239.
  42. Wesselius-De Casparis A, Braadbaart S, Bergh-Bohlken GE, Mimica M. Treatment of chronic constipation with lactulose syrup: results of a double-blind study. Gut 1968;9:84-86. https://doi.org/10.1136/gut.9.1.84
  43. Rouse M, Chapman N, Mahapatra M, Grillage M, Atkinson SN, Prescott P. An open, randomised, parallel group study of lactulose versus ispaghula in the treatment of chronic constipation in adults. Br J Clin Pract 1991;45:28-30.
  44. Lee JS, Kim YD, Im HH, et al. The effect of lactulose on the colon transit and the various symptoms of constipation in patients with functional constipation. Korean J Neurogastroenterol Motil 2006; 12:127-135.
  45. Tack J, Müller-Lissner S. Treatment of chronic constipation: current pharmacologic approaches and future directions. Clin Gastroenterol Hepatol 2009;7:502-508; quiz 496. https://doi.org/10.1016/j.cgh.2008.12.006
  46. Bosshard W, Dreher R, Schnegg J, Büla CJ. The treatment of chronic constipation in elderly people: an update. Drugs Aging 2004;21:911-930. https://doi.org/10.2165/00002512-200421140-00002
  47. Stern FH. Constipation: an omnipresent symptom: effect of a preparation containing prune concentrate and cascarin. J Am Geriatr Soc 1966;14:1153-1155.
  48. Kinnunen O, Winblad I, Koistinen P, Salokannel J. Safety and efficacy of a bulk laxative containing senna versus lactulose in the treatment of chronic constipation in geriatric patients. Pharmacology 1993;47(Supp 1):S253-S255.
  49. Connolly P, Hughes IW, Ryan G. Comparison of "Duphalac" and "irritant" laxatives during and after treatment of chronic constipation: a preliminary study. Curr Med Res Opin 1974;2: 620-625.
  50. Pers M, Pers B. A crossover comparative study with two bulk laxatives. J Int Med Res 1983;11:51-53.
  51. Williamson J, Coll M, Connolly M. A comparative trial of a new laxative. Nurs Times 1975;71:1705-1707.
  52. Odes HS, Madar Z. A double-blind trial of celandin, alovera and psyllium laxative preparation in adult patients with constipation. Digestion 1991;49:65-71. https://doi.org/10.1159/000200705
  53. MacLennan WJ, Pooler AFWM. A comparison of sodium picosulphate ("Laxoberal") with standardised senna ("Senokot") in geriatric patients. Curr Med Res Opin 1975;2:641-647. https://doi.org/10.1185/03007997409111877
  54. Passmore AP, Wilson-Davies K, Stoker C, Scott ME. Chronic constipation in long stay elderly patients: a comparison of lactulose and a senna-fibre combination. BMJ 1993;307:769-771. https://doi.org/10.1136/bmj.307.6907.769
  55. Kasdon SC, Morentin BO. The management of puerperal constipation with a senna preparation. J Int Coll Surg 1959;31: 455-458.
  56. Katz R. Evaluation of standardized senna in the treatment of refractory constipation. Med Press 1960;243:335-336.
  57. Corman ML. Management of postoperative constipation in anorectal surgery. Dis Colon Rectum 1979;22:149-151. https://doi.org/10.1007/BF02586804
  58. DeLuca VA. The management of chronic functional constipation in the severely incapacitated, aged nursing home patient. Med Counterpoint 1974;6:25-27.
  59. Delegge M, Kaplan R. Efficacy of bowel preparation with the use of a prepackaged, low fibre diet with a low sodium, magnesium citrate cathartic vs. a clear liquid diet with a standard sodium phosphate cathartic. Aliment Pharmacol Ther 2005;21:1491-1495. https://doi.org/10.1111/j.1365-2036.2005.02494.x
  60. Verghese VJ, Ayub K, Quershi W, Taupo T, Graham DY. Low-salt bowel cleansing preparation (LoSo Prep) as preparation for colonoscopy: a pilot study. Aliment Pharmacol Ther 2002; 16:1327-1331. https://doi.org/10.1046/j.1365-2036.2002.01295.x
  61. Kienzle-Horn S, Vix JM, Schuijt C, Peil H, Jordan CC, Kamm MA. Efficacy and safety of bisacodyl in the acute treatment of constipation: a double-blind, randomized, placebo-controlled study. Aliment Pharmacol Ther 2006;23:1479-1488. https://doi.org/10.1111/j.1365-2036.2006.02903.x
  62. Manabe N, Cremonini F, Camilleri M, Sandborn WJ, Burton DD. Effects of bisacodyl on ascending colon emptying and overall colonic transit in healthy volunteers. Aliment Pharmacol Ther 2009;30:930-936. https://doi.org/10.1111/j.1365-2036.2009.04118.x
  63. Mueller-Lissner S, Kamm MA, Wald A, et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation. Am J Gastroenterol 2010;105:897-903. https://doi.org/10.1038/ajg.2010.41
  64. Kienzle-Horn S, Vix JM, Schuijt C, Peil H, Jordan CC, Kamm MA. Comparison of bisacodyl and sodium picosulphate in the treatment of chronic constipation. Curr Med Res Opin 2007;23: 691-699. https://doi.org/10.1185/030079907X178865
  65. Hyland CM, Foran JD. Dioctyl sodium sulphosuccinate as a laxative in the elderly. Practitioner 1968;200:698-699.
  66. Castle SC, Cantrell M, Israel DS, Samuelson MJ. Constipation prevention: Empiric use of stool softeners questioned. Geriatrics 1991;46:84-86.
  67. Fain AM, Susat R, Herring M, Dorton K. Treatment of constipation in geriatric and chronically ill patients: a comparison. South Med J 1978;71:677-680. https://doi.org/10.1097/00007611-197806000-00022
  68. Chapman RW, Sillery J, Fontana DD, Matthys C, Saunders DR. Effect of oral dioctyl sodium sulfosuccinate on intake-output studies of human small and large intestine. Gastroenterology 1985;89:489-493.
  69. McRorie JW, Daggy BP, Morel JG, Diersing PS, Miner PB, Robinson M. Psyllium is superior to docusate sodium for treatment of chronic constipation. Aliment Pharmacol Ther 1998; 12:491-497. https://doi.org/10.1046/j.1365-2036.1998.00336.x
  70. Kamm MA, Müller-Lissner S, Tally NJ, et al. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. Am J Gastroenterol 2005; 100:362-372. https://doi.org/10.1111/j.1572-0241.2005.40749.x
  71. Tack J, Müller-Lissner S, Bytzer P, et al. A randomized controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut 2005;54:1707-1713. https://doi.org/10.1136/gut.2005.070789
  72. Choi H, Yoon SH, Lee WC, et al. Factors affecting the efficacy of tegaserod in patients with chronic constipation. Intest Res 2007;5: 170-176.
  73. Muller-Lissner S, Kamm MA, Musoglu A, Earnest DL, Dunger- Baldauf C, Shetzline MA. Safety, tolerability, and efficacy of tegaserod over 13 months in patients with chronic constipation. Am J Gastroenterol 2006;101:2558-2569. https://doi.org/10.1111/j.1572-0241.2006.00789.x
  74. Kim YS, Choi SC, Park JM, et al. The effect of tegaserod on symptoms and quality of life in Korean women with irritable bowel syndrome with constipation. J Neurogastroenterol Motil 2010;16:61-70. https://doi.org/10.5056/jnm.2010.16.1.61
  75. Loughlin J, Quinn S, Rivero E, et al. Tegaserod and the risk of cardiovascular ischemic events: an observational cohort study. J Cardiovasc Pharmacol Ther 2010;15:151-157. https://doi.org/10.1177/1074248409360357
  76. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebocontrolled trial of prucalopride for severe chronic constipation. N Engl J Med 2008;358:2344-2354. https://doi.org/10.1056/NEJMoa0800670
  77. Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009;58: 357-365. https://doi.org/10.1136/gut.2008.162404
  78. Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation: a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009;29:315-328. https://doi.org/10.1111/j.1365-2036.2008.03884.x
  79. Camilleri M, Beyens G, Kerstens R, Robinson P, Vandeplassche L. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil 2009;21:1256-e117. https://doi.org/10.1111/j.1365-2982.2009.01398.x
  80. Camilleri M, Vazquez-Roque MI, Burton D, et al. Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonists, ATI-7505, in humans. Neurogastroenterol Motil 2007;19:30-38. https://doi.org/10.1111/j.1365-2982.2006.00865.x
  81. Manini ML, Camilleri M, Goldberg M, et al. Effects of velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil 2010;22:42-49.
  82. Yang US, Cho JH, Koo JY, et al. The effect of cisapride tartrate in patients with functional dyspepsia and functional constipation. Korean J Gastrointest Motil 2001;7:36-46.
  83. Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther 2007;25:1351-1361. https://doi.org/10.1111/j.1365-2036.2007.03320.x
  84. Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroentrol 2008;103:170-177. https://doi.org/10.1111/j.1572-0241.2007.01524.x
  85. Barish CF, Drossman D, Johanson JF, Ueno R. Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci 2010;55:1090-1097. https://doi.org/10.1007/s10620-009-1068-x
  86. Johnston JM, Kurtz CB, Drossman DA, et al. Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroenterol 2009;104:125-132. https://doi.org/10.1038/ajg.2008.59
  87. Lembo AJ, Kurtz CB, Macdougall JE, et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 2010; 138:886-895. https://doi.org/10.1053/j.gastro.2009.12.050
  88. Paulson DM, Kennedy DT, Donovick RA, et al. Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction: a 21-day treatment-randomized clinical trial. J Pain 2005;6:184-192. https://doi.org/10.1016/j.jpain.2004.12.001
  89. Webster L, Jansen JP, Peppin J, et al. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain 2008;137:428-440. https://doi.org/10.1016/j.pain.2007.11.008
  90. Delaney CP, Weese JL, Hyman NH, et al. Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery. Dis Colon Rectum 2005;48:1114-1125; discussion 1125-1126. https://doi.org/10.1007/s10350-005-0035-7
  91. Viscusi ER, Goldstein S, Witkowski T, et al. Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: result of a randomized, double-blind, controlled study. Surg Endosc 2006;20:64-70. https://doi.org/10.1007/s00464-005-0104-y
  92. Buchler MW, Seiler CM, Monson JR, et al. Clinical trial: alvimopan for the management of post-operative ileus after abdominal surgery: result of an international randomized, doubleblind, multicentre, placebo-controlled clinical study. Aliment Pharmacol Ther 2008;28:312-325. https://doi.org/10.1111/j.1365-2036.2008.03696.x
  93. Herzog TJ, Coleman RL, Guerrieri JP Jr, et al. A double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomy. Am J Obstet Gynecol 2006;195:445-453. https://doi.org/10.1016/j.ajog.2006.01.039
  94. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008;358:2332-2343. https://doi.org/10.1056/NEJMoa0707377
  95. Portenoy RK, Thomas J, Moehl Boatwright ML, et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage 2008;35:458-468. https://doi.org/10.1016/j.jpainsymman.2007.12.005
  96. Slatkin N, Thomas J, Lipman AG, et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol 2009;7:39-46.
  97. Chamberlain BH, Cross K, Winston JL, et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. J Pain Symptom Manage 2009;38:683-690. https://doi.org/10.1016/j.jpainsymman.2009.02.234
  98. Parkman HP, Rao SS, Reynolds JC, et al. Neurotrophin-3 improves functional constipation. Am J Gastroenterol 2003;98: 1338-1347. https://doi.org/10.1111/j.1572-0241.2003.t01-1-07477.x
  99. Enmmanuel AV, Kamn MA. Response to a behavioural treatment, biofeedback, in constipated patients is associated with improved gut transit and autonomic innervation. Gut 2001;49:214-219. https://doi.org/10.1136/gut.49.2.214
  100. Enck P. Biofeedback training in disordered defecation: a critical review. Dig Dis Sci 1993;38:1953-1960. https://doi.org/10.1007/BF01297069
  101. Rao SS, Welcher KD, Pelsang RE. Effects of biofeedback therapy on anorectal function in obstructive defecation. Dig Dis Sci 1997;42:2197-2205. https://doi.org/10.1023/A:1018846113210
  102. Chiarioni G, Salandini L, Whitehead WE. Biofeedback benefits only patients with outlet dysfunction, not patients not patients with isolated slow transit constipation. Gastroenterology 2005; 129:86-97. https://doi.org/10.1053/j.gastro.2005.05.015
  103. Chiotakou-Faliakou E, Kamm MA, Roy AJ, Storrie JB, Turner IC. Biofeedback provides long term benefit for patients with intractable, slow and normal transit constipation. Gut 1998;42: 517-521. https://doi.org/10.1136/gut.42.4.517
  104. Mason HJ, Serrano-Ikkos E, Kamm MA. Psychological state and quality of life in patients having behavioral treatment (biofeedback) for intractable constipation. Am J Gastroenterol 2002;97:3154-3159. https://doi.org/10.1111/j.1572-0241.2002.07113.x
  105. Rao SS, Valestin J, Brown CK, Zimmerman B, Schulze K. Long-term efficacy of biofeedback therapy for dyssynergic defecation: randomized controlled trial. Am J Gastroenterol 2010;105:890-896.　 https://doi.org/10.1038/ajg.2010.53
  106. Herve S, Savoye G, Behbahani A, Leroi AM, Denis P, Ducrotté, et al. Results of 24-h manometric recording of colonic motor activity with endoluminal instillation of bisacodyl in patients with severe chronic slow triansit constipation. Neurogastroenterol Motil 2004;16:397-402. https://doi.org/10.1111/j.1365-2982.2004.00535.x
  107. Jeong JH, Choi JS, Seo YJ, Kim JH. Biofeedback therapy in patients with nonrelaxing puborectalis syndrome: are there differences of therapeutic effect according to methods of diagnosis? J Korean Soc Coloproctol 2001;17:26-32.
  108. Jung KW, Myung SJ, Byeon JS, et al. Response to biofeedback therapy for patients with rectal hyposensitivity. Intest Res 2008;6:56-69.
  109. Chang HS, Myung SJ, Yang SK, et al. Electrical stimulation effect in constipated patients with impaired rectal sensation. Korean J Gastrointest Motil 2002;8:160-166.
  110. Lee BH, Kim N, Kang SB, et al. The long-term clinical efficacy of biofeedback therapy for patients with constipation or fecal incontinence. J Neurogastroenterol Motil. 2010;16:177-185. https://doi.org/10.5056/jnm.2010.16.2.177
  111. Binnie NR, Smith AN, Creasey GH, Edmond P. Constipation associated with spinal cord injury: the effect of pelvic parasympathetic stimulation by the Brindley stimulator. Paraplegia 1991;29:463-469. https://doi.org/10.1038/sc.1991.63
  112. Pescatori M, Meglio M, Cioni B, Cologrande C Colonic motility in two constipated neurological patients treated by spinal cord stimulation. In: Wienbeck M, ed. Motility of the digestive tract. New York: Raven Press, 1982:541-546.
  113. Herve S, Savoye G, Behbahani A, Leroi AM, Denis P, Ducrotté P. Results of 24-h manometric recording of colonic motor activity with endoluminal instillation of bisacodyl in patients with severe chronic slow transit constipation. Neurogastroenterol Motil 2004; 16:397-402. https://doi.org/10.1111/j.1365-2982.2004.00535.x
  114. Ganio E, Masin A, Ratto C, et al. Short-term sacral nerve stimulation for functional anorectal and urinary disturbances: results in 40 patients: evaluation of new option for anorectal functional disorders. Dis Colon Rectum 2001;44:1261-1267. https://doi.org/10.1007/BF02234782
  115. Malouf AJ, Wiesel PH, Nicholls T, Nicholls RJ, Kamm MA. Short-term effects of sacral nerve stimulation for idiopathic slow transit constipation. World J Surg 2002;26:166-170. https://doi.org/10.1007/s00268-001-0202-5
  116. Kenefick NJ, Nicholls RJ, Cohen RG, Kamm MA. Permanent sacral nerve stimulation for treatment of idiopathic constipation. Br J Surg 2002;89:882-888. https://doi.org/10.1046/j.1365-2168.2002.02132.x
  117. Kenefick NJ, Vaizey CJ, Cohen CR, Nicholls RJ, Kamm MA. Double-blind placebo-controlled crossover study of sacral nerve stimulation for idiopathic constipation. Br J Surg 2002;89:1570-1571. https://doi.org/10.1046/j.1365-2168.2002.02278.x
  118. Kamm MA, Dudding TC, Melenhorst J, et al. Sacral nerve stimulation for intractable constipation. Gut 2010;59:333-340. https://doi.org/10.1136/gut.2009.187989
  119. Holzer B, Rosen HR, Novi G, et al. Sacral nerve stimulation in patients with severe constipation. Dis Colon Rectum 2008;51: 524-529. https://doi.org/10.1007/s10350-007-9160-9
  120. Vitton V, Roman S, Damon H, Barth X, Mion F. Sacral nerve stimulation and constipation: still a long way to go. Dis Colon Rectum 2009;52:752-753.
  121. Dinning PG, Fuentealba SE, Kennedy ML, Lubowski DZ, Cook IJ. Sacral nerve stimulation induces pan-colonic propagating pressure waves and increases defecation frequency in patients with slow-transit constipation. Colorectal Dis 2007;9:123-132. https://doi.org/10.1111/j.1463-1318.2006.01096.x
  122. Song HK, Myung SJ, Yang SK, et al. Noninvasive sacral nerve stimulation for idiopathic slow transit constipation: short term clinical and physiologic effects. Korean J Neurogastroenterol Motil 2003;9:134-141.
  123. Knowles CH, Scott M, Lunniss PJ. Outcome of colectomy for slow transit constipation. Ann Surg 1999;230:627-638. https://doi.org/10.1097/00000658-199911000-00004
  124. Wexner SD, Daniel N, Jagelman DG. Colectomy for constipation: physiologic investigation is the key to success. Dis Colon Rectum 1991;34:851-856. https://doi.org/10.1007/BF02049695
  125. Lee HC, Hong SN, Lee JH, et al. Clinical features and functional outcome of the patients with idiopathic chronic constipation who underwent surgical treatment. Korean J Gastrointest Motil 2001;7:204-215.
  126. Nam KH, Sohn SK. Clinical results of subtotal colectomy in chronic constipation patients. J Korean Soc Coloproctol 2000;16: 395-401.
  127. Lim SW, Oh SH, Lee WY. Clinical analysis of total colectomy for chronic idiopathic constipation. J Korean Soc Coloproctol 2000; 16:150-155.